Echarte-Morales Julio, Barreiro-Pérez Manuel, Nombela-Franco Luis, Freixa Xavier, Cruz-González Ignacio, Sánchez-Recalde Ángel, Arzamendi Dabit, Baz Jose Antonio, Mon Matias, Sanchis Laura, Laffond Ana E, Rodríguez Luis Manuel Domínguez, Li Chi Hion, Jiménez Pilar, Altisent Omar Abdul-Jawad, Blanco Fabian, Fernández-Golfín Covadonga, Menduiña Irene, Estévez-Loureiro Rodrigo
Department of Cardiology, University Hospital Alvaro Cunqueiro, Vigo, Spain.
Cardiovascular Research Group, Department of Cardiology, University Hospital Alvaro Cunqueiro, Fundación Biomédica Galicia Sur, Servizo Galego de Saude, University of Vigo, Vigo, Spain.
Catheter Cardiovasc Interv. 2025 Aug;106(2):1153-1161. doi: 10.1002/ccd.31662. Epub 2025 Jun 4.
Transcatheter tricuspid valve replacement (TTVR) is a novel technique for the treatment of symptomatic tricuspid regurgitation (TR).
This study aims to present the initial experience in Spain and report short-term outcomes of this therapy.
This was a multicenter, retrospective registry including 48 patients who underwent percutaneous tricuspid valve replacement between April 2022 and September 2024. The primary efficacy objectives were procedural success and the degree of regurgitation at discharge. The primary safety objectives included all-cause mortality, hospitalization for heart failure, and other major adverse cardiovascular events.
A total of 48 patients were included (79 [72-82] years, 75% women, TRISCORE 5 [4-6] points). Sixty-three percent of the patients were in New York Heart Association (NYHA) functional class ≥ III. TR was predominantly of secondary etiology (87%). Procedural success was 98%. The entire treated population achieved TR ≤ 2+ at discharge (100%), and TR ≤ 1+ was achieved in 94% of patients. A permanent pacemaker was implanted in 15.8% of patients. At 30 days, overall mortality was 2.2%, 82% of patients were in NYHA class I/II, and 100% and 94% had TR grades ≤ 2+ and ≤ 1+, respectively.
Percutaneous tricuspid valve replacement proved to be effective and safe, with a high procedural success rate and a low incidence of adverse events. At 30 days, a significant reduction in TR grade was observed, along with an improvement in functional class.
经导管三尖瓣置换术（TTVR）是治疗有症状三尖瓣反流（TR）的一项新技术。
本研究旨在介绍西班牙的初步经验并报告该治疗方法的短期结果。
这是一项多中心回顾性登记研究，纳入了2022年4月至2024年9月期间接受经皮三尖瓣置换术的48例患者。主要疗效指标为手术成功率和出院时的反流程度。主要安全性指标包括全因死亡率、因心力衰竭住院以及其他主要不良心血管事件。
共纳入48例患者（年龄79[72 - 82]岁，75%为女性，TRISCORE评分为5[4 - 6]分）。63%的患者纽约心脏协会（NYHA）心功能分级≥III级。TR主要为继发性病因（87%）。手术成功率为98%。所有接受治疗的患者出院时TR均≤2+（100%），94%的患者TR≤1+。15.8%的患者植入了永久性起搏器。30天时，总死亡率为2.2%，82%的患者NYHA分级为I/II级，100%和94%的患者TR分级分别≤2+和≤1+。
经皮三尖瓣置换术被证明是有效且安全的，手术成功率高，不良事件发生率低。30天时，观察到TR分级显著降低，同时心功能分级有所改善。
